Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone

Giandomenico Roviello, Roberto Petrioli, Alberto Bonetta, Raffaele Conca, Maria Grazia Rodriquenz, Michele Aieta

Research output: Contribution to journalArticle


The aim of this retrospective study is to evaluate the activity and safety of a steroidal switch from prednisone to dexamethasone in patients with advanced, heavily pre-treated, castration-resistant prostate cancer (CRPC) who progressed on abiraterone acetate. Treatment consisted of oral daily abiraterone plus dexamethasone (0.5 mg once daily) administered until disease progression or unacceptable toxicity. Thirty-six patients were evaluated: all men underwent a prior treatment with enzalutamide. A PSA decrease ≥50% was observed in 11% of patients; median progression-free survival was 10.8 weeks (95% CI: 9.2–16), and median survival was 17.6 weeks (95% CI: 15.8–28.8). Better efficacy and survival were observed in the subgroup of patients treated with abiraterone acetate prior for a period >3 months; treatment was well tolerated, and no grade 3–4 toxicities were observed. Our findings did not suggest the use of steroid switch in all CRPC who were heavily pre-treated. However, the switch could be an option for patients who responded well to prior abiraterone acetate treatment.

Original languageEnglish
Pages (from-to)1110-1115
Number of pages6
JournalInvestigational New Drugs
Issue number6
Publication statusPublished - Dec 1 2018



  • abiraterone acetate
  • dexamethasone
  • prednisone

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this